Why Clinical Trial Site Reliability Matters

The reliability of clinical trial sites and principal investigators is critical for:

  • Ensuring timely patient recruitment

  • Maintaining accurate data integrity

  • Achieving a study's clinical endpoints

  • Staying on time and on budget

Poorly performing sites or unreliable investigators can lead to:

  • Extended recruitment periods

  • Longer study durations

  • Inflated baseline scores

  • Compromised data

All of which increase costs and delay critical milestones. For investors and shareholders, this translates into financial risk, potential loss of market opportunity, and uncertainty in product efficacy outcomes. Addressing site and investigator reliability mitigates these risks, enhances trial efficiency, and maximizes the potential for positive drug effects, ultimately protecting and enhancing shareholder value.

Who we are

Tectonic Investor Intelligence was founded by clinical trial professionals with over 60 years of combined experience. Our proprietary AI analytical models are informed by extensive historical case studies spanning venture-backed, small-cap, and large pharmaceutical companies globally. Our founders recognized a recurring pattern of promising assets failing clinical trials not due to inherent limitations of the therapy itself, but rather as a result of suboptimal clinical trial management. This observation led to the development of our unique clinical trial success factors, which have demonstrated a strong correlation with trial and program outcomes.